Phase II Trial of Vandetanib (ZD6474, Caprelsa) in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 May 2017
At a glance
- Drugs Vandetanib (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 07 Feb 2017 Planned End Date changed from 31 Aug 2018 to 31 Aug 2023.
- 07 Feb 2017 Planned primary completion date changed from 15 Sep 2017 to 15 Sep 2022.